ARCHIVES

FDA Proposes New User Fees for Generics and Biosimilar Products

This article is from The Cancer Letter archive.

Vol. 38 No. 03 | January 20, 2012

Download PDF Visit The Full Archive

Related Articles

With A Flat Budget, Niederhuber Outlines NCI Priorities In Speech To ASCO Meeting.

June 13, 2008

NCI RFAs Available

May 5, 2000

Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia

October 31, 2003

Groups Urge Passage of Health Care Reform Legislation

January 29, 2010

NIH Proposes Center for Cell Biology

February 19, 1993

FDA: Oncology Division Director Delap Promoted In Agency

May 29, 1998